Phase II trial of prednimustine, L-1031, (NSC-134087) in advanced breast cancer.
The therapeutic effect of prednimustine was studied in 35 patients with advanced breast cancer resistant to previous cytotoxic and/or endocrine therapy. Response (PR + CR) was obtained in 14 patients (40%) of a median duration of five months. Among the 14 responding patients, 10 were resistant to previous endocrine therapy and chemotherapy, in all cases including alkylating agents, and 4 were resistant to previous endocrine therapy. Hematologic toxicity was rather pronounced, but other toxicities were only moderate.
D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000188:drug therapy*; D002699:Chlorambucil / Q000031:analogs & derivatives*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D011238:Prednimustine / Q000009:adverse effects / Q000627:therapeutic use*; D011605:Psychoses, Substance-Induced / Q000209:etiology; D013921:Thrombocytopenia / Q000139:chemically induced; D013997:Time Factors; D014839:Vomiting / Q000139:chemically induced
D002699:Chlorambucil; D011238:Prednimustine